ÂÜÀòÂÒÂ×

Abeba Demelash Ph.D. has had a varied and accomplished career in research. Abeba began their career in 2000 as a Research Scientist at Sahlgrenska University Hospital, where they developed study designs and conducted cell-based assays to define apoptotic signaling pathways in thyroid primary cells and neuronal cell differentiation/proliferation. Abeba also earned their Ph.D. in this role, with their dissertation, "Regulation of Apoptosis in the Thyroid Epithelium," resulting in several awards and travel grants and one first-authored peer-reviewed publication.

In 2006, they began working as a Research Scientist at the National Institutes of Health, National Cancer Institute (NIH/NCI). In this role, they identified a novel mechanism of the CDK5, P35, and HASH cell signaling pathways in the initiation and progression of non-small cell lung cancer (NSCLC), leading to two peer-reviewed publications. Abeba also conceived and performed exploratory mouse model studies, including crossing and maintaining colonies of transgenic mice, genotyping, injections, dissection, tissue processing, molecular histology of mouse diseases, immunohistochemistry, Laser capture microdissection (LCM), and data analysis.

In 2017, they joined GLG (Gerson Lehrman Group) as a Council Member. In 2019, they began working at Ambys Medicines, where they have held three roles: Senior Scientist I, Scientist II, Cell Therapy Team, and Associate Scientist, Cell/Gene Therapy Team.

Abeba Demelash Ph.D. received their Ph.D. at Sahlgrenska University Hospital in Cell and Molecular Biology from the University of Gothenburg in 2004. Prior to that, they obtained a Master's Degree in Cellular and Molecular Biology from the same university, and a Bachelor's Degree in Cell Biology from the same university.